Molecular Staging is addressing this demand with a portfolio of products and services based on technologies that are transforming the detection and measurement of both proteins and nucleic acids.
- The Molecular Biology of HIV/AIDS
- The epigenetics of cancer, a recent view
- Structure of an enzyme and its in hibitor
- Rolling Circle Amplification Technology–Technical Details
- Development and morphogenesis: potentialities from common patterns
- Cancer as a Disease of the Cell Cycle
- Human skin analysis
- HYBRIDIZATION METHODS IN LIQUID PHASE
- PROPERTIES OF DNA
- Employment Opportunities
- Apoptotic mechanisms of granzymes in CTL lysis
- The mitofusin 2 in mitochondrial energization
- Induction therapy of autophagy and apoptosis in melanoma cells
- Employment Opportunities at MSI
- Parallel evolution of the venom of snakes and integrin
It is no novelty influence the monumental work of Joan Massagué and his team from the Memorial Sloan-Kettering Cancer Center in New York, where he is director of Biology and Cancer Genetics. Massagué, awarded in 2004 with the Prince of Asturias Award for Technical and Scientific Research, has for two decades in the United States to develop his career and achieved great success in research. Massagué is also a researcher at the prestigious Howard Hughes Institute, deputy director of the Institute of Biomedical Research and a member of the National Academy of Sciences of the United States and the European Molecular Biology Organization .
Joan Massagué has spent most of his research in the field of cell division and processes associated with tumor metastasis, striving to unite the work of basic research and clinical, laboratory and patient. Massagué and his many disciples, some of them researchers and practicing in Spain, have consolidated a few years deciphering some of the genes involved in the spread of tumors from one organ to another.
His numerous works, widely cited in scientific literature, highlights the role of some genes in the development of new tumors and in particular the decisive intervention of others, independently or in conjunction with the above-in the spread of cancer cells to other organs. Among these studies, the most recent open the possibility of new drug therapies designed based on the patient’s genetic profile, conferring specificity tremendously important to save the diversity of causes involved in the occurrence of a given tumor.
The gene hedgehog (hh) was initially identified as a key gene in embryonic development of the fruit fly, Drosophila melanogaster. While Drosophila has only one hedgehog gene, vertebrates have three peers. These proteins are secreted extracellular ligands by a group of cells during organ formation in the embryo. In the adult hedgehog maintains and regulates stem cells in many tissues, being instrumental in regenerative processes. There is also a close relation between HH signaling pathway and the development of tumors, genetic alterations observed that stimulate the growth of tumor cells in the digestive tract, lung and prostate .
And Molecular Genetic studies of this approach has shown its relationship with cholesterol and lipids. Thus, both Drosophila and vertebrates, the active molecule is modified by HH cholesterol, varying the diffusion of HH activity through epithelial tissue and their signaling. In addition, the operation of the route depends on intracellular sterol content, so the appearance of the same type of malformations during pregnancy, in patients deficient in the signaling pathway of HH and in patients with defects in cholesterol synthesis could be caused by the lack of signs of HH.
This study demonstrates that in Drosophila, hedgehog is transported through the epithelial cells of a lipoprotein in the same way that lipids and cholesterol are transported through the bloodstream. And as expected, the receiver of the road, patched, acts as a receptor of low density lipoproteins (LDLR) and its ability to modulate lipid homeostasis. With these results we get energy metabolism correlate with embryonic development and carcinogenesis, a potential new therapeutic target for the treatment of various cancers.
Reprogramming somatic cells into pluripotent stem cells mature is one of the top scientific advances of recent years. The generation of iPS cells specific to a patient may have applications in cellular therapy. Three years ago, researchers at the University of Tokyo (Japan) first introduced the technique of transformation of adult cells in other mouse that had the potential of embryonic, 1 thus opening a new alternative to obtaining pluripotent cells without being embryonic stem cells. Later, U.S. researchers obtained human iPS cells for the first time. Read the rest of this entry »
How does a DNA molecule encoding a protein?
Translation: The plant cell responsible for the synthesis of proteins is the ribosome. The specific molecules that will move the amino acids (building blocks of proteins) following the guidelines issued by the mRNA is the tRNA. Each tRNA has a specific anticodon (composed of three bases). Read the rest of this entry »
DNA strands that form the helix have opposite orientations: one is in the direction 5′-3’y its complement in the 3′-5 ‘. The breaking of hydrogen bonds by heat, alkali or various chemical, produces the physical separation of the two strands of DNA in a process called denaturation. The heat denaturation is complete at 90 ° C and excess alkali pHs 11.3. In both cases the process is reversible, and the disappearance of the denaturing agent occurs renaturation of the molecule, ie the re-acquisition of lost-helical structure. ‘
MSI will build broad usage of the RCAT™ platform and other core technologies through the development of superior diagnostic and genomics tools. To accomplish this, we will pursue vigorous internal development and the establishment of strategic collaborations and licensing agreements to popularize the company’s technology base.
Read the rest of this entry »
If your scientific goals include biomarker discovery, validation, or assessing drug response, coverage is vital. MSI offers ultra-multiplexed protein analysis designed to yield a comprehensive look at the biology underlying disease and drug response.
Read the rest of this entry »
In addition to RCATTM and MDA MSI has exclusively licensed from Yale University the worldwide rights to two technologies: allele frequency distortion (AFD) and multiparametric fluorescent in-situ hybridization (MFISHTM). These additional technologies increase opportunities to develop new platforms, products and services.
Read the rest of this entry »
Many disease states require panels of different tests to be conducted simultaneously (multiplexing) to achieve a clinically complete picture. To date, efforts to multiplex tests have been constrained by issues of background noise or interference, or the requirement for extremely sensitive methods of analyte detection.
One of the unique features of RCAT is that during the amplification process the signal remains tethered to the analyte of interest. This effectively enables multiplexing capabilities with unprecedented sensitivity and specificity.
Current applications of RCAT technology have been developed in a multiplexing format enabling greater than 100 different proteins to be measured simultaneously with significantly greater sensitivity than other current methods. Read the rest of this entry »